Study of the SARS-COV-2 (COVID-19) Serological Profile of an Army Training Hospital Staff (SEROSARSCOV)

Direction Centrale du Service de Santé des Armées

Status: Completed

Conditions: Sars-CoV2

Treatments: Diagnostic Test: Anti-SARS-CoV2 Serology; Other: Questionnaire

Study type: Observational

Funder types: Other

Identifiers

NCT04387838

2020-COVID19-10

2020-A01028-31 (Other Identifier)

Details and patient eligibility

About

Emerging in China in December 2019, Covid-19, whose pathogen is SARS-Cov-2, was declared a global pandemic in March 2020. The clinical presentation is highly variable, ranging from asymptomatic forms to acute respiratory distress and even death. Transmission occurs through droplets, with a R0 of approximately 3.

Rapidly, population protection measures were put in place by governments, including the confinement of all persons whose functions were not considered essential and the closure of educational institutions.

Health care institutions are places at risk of Covid-19 transmission and hospital staff are particularly exposed, either through direct contact with patients, contact with exposed persons or through the environment. In order to protect personnel, hygiene measures were immediately recalled and reinforced.

This study is aimed at evaluating the incidence rate of anti-SARS-Cov2 seroconversion over 2 months among hospital staff, without any supposed anti-Covid treatment 19.

Enrollment: 845 patients

Sex: All

Ages: 18 to 62 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Army Training Hospital staff

Exclusion criteria

• Individuals who have already been confirmed Covid-19 positive
• Individuals taking preventive anti-Covid-19 therapy or considering participating in anti-Covid-19 therapy study
• Individuals on hydroxychloroquine
• Pregnant or breastfeeding women
• Non-permanent staff during the study period
• Individuals identified for a detachment outside the metropole during the study period

Trial design

845 participants in 1 patient group

Anti-SARS-CoV2 serological status

Description:

At Day 0, a blood sample is collected by venipuncture and a questionnaire is being filled. The anti-SARS-CoV2 serological status is measured by automated microplate ELISA technique on the EVOLIS analyzer (Biorad®), using reagent kits from EUROIMMUN France. For individuals who are anti-SARS-CoV2 seronegative, the same intervention is made at Day 30 and D60. For the individuals who are anti-SARS-CoV2 seropositive, the study follow-up is stopped.

Treatment:

Diagnostic Test: Anti-SARS-CoV2 Serology

Other: Questionnaire